Assessing TP53 status in human tumours to evaluate clinical outcome
- 1 December 2001
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 1 (3), 233-239
- https://doi.org/10.1038/35106009
Abstract
TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?Keywords
This publication has 69 references indexed in Scilit:
- ATM: A mediator of multiple responses to genotoxic stressOncogene, 1999
- Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functionsOncogene, 1999
- Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patientsEuropean Journal of Cancer, 1999
- Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinomaOncogene, 1999
- Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancerOncogene, 1998
- A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient miceNature Genetics, 1995
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Different Tumor-Derived p53 Mutants Exhibit Distinct Biological ActivitiesScience, 1990
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989